Levosimendan Mercapharm

Levosimendan, the active ingredient in Levosimendan Mercapharm, is a calcium sensitizer and K‑ATP channel opener presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure in adult patients.

GNH USA supplies Levosimendan Mercapharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levosimendan is indicated for conditions involving acute cardiac dysfunction, primarily within the heart‑failure disease family.

- Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. - Low cardiac output syndrome after cardiac surgery: supports hemodynamic stability during the postoperative period. - Severe chronic heart failure (off‑label): may be used under specialist supervision to enhance myocardial performance.

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypotension: sudden drop in blood pressure during infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Dizziness: feeling light‑headed, especially when standing. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmia: potentially life‑threatening heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Severe hypotension: profound blood pressure fall requiring intervention. - Anaphylactic reaction: rare severe allergic response. - Sudden cardiac death: extremely rare but fatal outcome.

When using Levosimendan, clinicians should observe specific safety measures to minimize risk.

- Blood pressure monitoring: check systolic pressure before and during infusion. - Electrolyte assessment: correct potassium and magnesium abnormalities prior to therapy. - Renal function evaluation: adjust use in patients with severe renal impairment. - Concomitant vasodilators: avoid co‑administration with other potent vasodilators. - Arrhythmia surveillance: discontinue if serious ventricular arrhythmias develop. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with other cardiovascular agents, requiring careful management.

Major Interactions (Avoid): - Other vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Potassium channel blockers (e.g., nicorandil): additive vasodilatory effect. - Sodium nitroprusside: excessive vasodilation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired increase in cardiac output. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Diuretics: watch for electrolyte shifts.